scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it has commenced an underwritten public offering of shares of its common stock. All shares of common stock to be sold in the offering will be offered by scPharmaceuticals. In addition, the underwriters will have a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price less the underwriting discount. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Jefferies and SVB Leerink are acting as joint book-running managers for the offering.

The shares of common stock are offered pursuant to a shelf registration statement on Form S-3 (File No. 333-229120), including a base prospectus, filed by scPharmaceuticals on January 3, 2019 and declared effective by the Securities and Exchange Commission, or SEC, on February 11, 2019. The offering will be made only by means of a prospectus.